Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.51 |
| ▸ | REN | P00797 | 6/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.50 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220702 | 0.91 | REN (0.58) | RENKLK5 | |
| SCHEMBL30318981 | 0.91 | REN (0.58) | RENKLK5 | |
| SCHEMBL4338707 | 0.88 | ENPP2 (0.46) | YAP1 | |
| SCHEMBL4338710 | 0.88 | ENPP2 (0.46) | YAP1 | |
| SCHEMBL5386298 | 0.88 | KLK5 (0.57) | RENKLK5 | |
| SCHEMBL5386289 | 0.88 | KLK5 (0.57) | RENKLK5 | |
| SCHEMBL7312642 | 0.87 | KLK5 (0.52) | YAP1RENKLK5BCL2PTPN1 | |
| SCHEMBL13630987 | 0.86 | REN (0.54) | YAP1RENKLK5BCL2PTPN1 | |
| SCHEMBL5945448 | 0.86 | REN (0.54) | YAP1RENKLK5BCL2PTPN1 | |
| SCHEMBL24066704 | 0.84 | KLK5 (0.50) | YAP1RENKLK5BCL2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | YAP1 4559/4885REN 796/4885KLK5 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.